Literature DB >> 8157358

Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines.

M A Hollingsworth1, J M Strawhecker, T C Caffrey, D R Mack.   

Abstract

We examined the steady-state expression levels of mRNA for the MUC1, MUC2, MUC3 and MUC4 gene products in 12 pancreatic tumor cell lines, 6 colon tumor cell lines, and one ileocecal tumor cell line. The results showed that 10 of 12 pancreatic tumor cell lines expressed MUC1 mRNA and that 7 of these 12 lines also expressed relatively high levels of MUC4 mRNA. In contrast, MUC2 mRNA was expressed at only low levels and MUC3 was not detected in the pancreatic tumor cell lines. All 7 intestinal tumor cell lines examined expressed MUC2, and 5 of 7 expressed MUC3; however only one expressed significant levels of MUC1 and 2 expressed low levels of MUC4 mRNA. This report of high levels of MUC4 mRNA expression by pancreatic tumor cells raises the possibility that mucin carbohydrate epitopes defined by antibodies such as DuPan 2 may be expressed on a second mucin core protein produced by pancreatic tumor cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157358     DOI: 10.1002/ijc.2910570212

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

Review 1.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

2.  MUC1 expressed in PanC1 cells decreases adhesion to type 1 collagen but increases contraction in collagen lattices.

Authors:  M J Hudson; G W Stamp; M A Hollingsworth; M Pignatelli; E N Lalani
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

Review 3.  Mucin-based targeted pancreatic cancer therapy.

Authors:  Maria P Torres; Subhankar Chakraborty; Joshua Souchek; Surinder K Batra
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  MUC2 Mucin and Butyrate Contribute to the Synthesis of the Antimicrobial Peptide Cathelicidin in Response to Entamoeba histolytica- and Dextran Sodium Sulfate-Induced Colitis.

Authors:  Eduardo R Cobo; Vanessa Kissoon-Singh; France Moreau; Ravi Holani; Kris Chadee
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

5.  MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas.

Authors:  M Saitou; M Goto; M Horinouchi; S Tamada; K Nagata; T Hamada; M Osako; S Takao; S K Batra; T Aikou; K Imai; S Yonezawa
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

Review 6.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

Review 7.  Deglycosylation of glycoproteins with trifluoromethanesulphonic acid: elucidation of molecular structure and function.

Authors:  Albert S B Edge
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

8.  Functions and regulation of MUC13 mucin in colon cancer cells.

Authors:  Brij K Gupta; Diane M Maher; Mara C Ebeling; Phillip D Stephenson; Susan E Puumala; Michael R Koch; Hiroyuki Aburatani; Meena Jaggi; Subhash C Chauhan
Journal:  J Gastroenterol       Date:  2013-10-07       Impact factor: 7.527

9.  Human mucin gene MUC4: organization of its 5'-region and polymorphism of its central tandem repeat array.

Authors:  S Nollet; N Moniaux; J Maury; D Petitprez; P Degand; A Laine; N Porchet; J P Aubert
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

Review 10.  Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis.

Authors:  Angela L McCleary-Wheeler; Gwen A Lomberk; Frank U Weiss; Günter Schneider; Muller Fabbri; Tara L Poshusta; Nelson J Dusetti; Sandra Baumgart; Juan L Iovanna; Volker Ellenrieder; Raul Urrutia; Martin E Fernandez-Zapico
Journal:  Cancer Lett       Date:  2012-10-13       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.